Contact
searchSearch
HMP Global
Login
News
Study Estimates the Total Lifetime Cost of Treating Patients With CLL in the US
04/12/2024

Grace Taylor

Grace Taylor
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan, MD, and colleagues estimated the total lifetime cost of treating patients with chronic lymphocytic leukemia in the US.
A recent study by Farrukh Awan,...
04/12/2024
Journal of Clinical Pathways
Nikolai Podoltsev video thumbnail.
Videos
Current Treatment Options and Recent Developments in Myelofibrosis
03/27/2024

Featuring Nikolai Podoltsev, MD, PhD

Featuring Nikolai Podoltsev, MD, PhD ...
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD, shares key insights from his session on managing myelofibrosis at ASH 2023 and looks at some of the exciting research on the horizon.
Nikolai Podoltsev, MD, PhD,...
03/27/2024
Journal of Clinical Pathways
Jing-Zhou Hou, MD, PhD
Videos
Clinical and Demographic Factors Impacting Treatment Selection for Patients With CLL in Community Oncology Settings
03/21/2024

Featuring Jing-Zhou Hou, MD, PhD

Featuring Jing-Zhou Hou, MD, PhD ...
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD, discusses how the standard of care for CLL has evolved among community oncologists since 2020 and how clinical and demographic factors impact treatment selection.
Jing-Zhou Hou, MD, PhD,...
03/21/2024
Journal of Clinical Pathways
News
Real-World Outcomes of Brexucabtagene Autoleucel Treatment in Patients With Relapsed or Refractory Mantle Cell Lymphoma With High-Risk Features
02/14/2024
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated real-world outcomes of brexu-cel treatment in patients with relapsed or refractory mantle cell lymphoma with high-risk features, including deletion of TP53 or 17p, Ki-67 proliferation index, and whether the...
A recent study investigated...
02/14/2024
Journal of Clinical Pathways
Conference Highlights
Highlights From the 65th ASH Annual Meeting & Exposition
02/09/2024
The American Society of Hematology Annual Meeting & Exposition was held in San Diego, California, December 9-12, 2023. Read our selection of online news coverage of the conference that features the discoveries, emerging therapies, and...
The American Society of Hematology Annual Meeting & Exposition was held in San Diego, California, December 9-12, 2023. Read our selection of online news coverage of the conference that features the discoveries, emerging therapies, and...
The American Society of...
02/09/2024
Journal of Clinical Pathways
News
The Use of Geriatric Assessment in Predicting Toxicities in Older Adults with Non-Hodgkin Lymphoma Receiving Systemic Chemotherapy
02/06/2024
Pallawi Torka, MD, and colleagues investigated whether a geriatric assessment or its component measures can predict toxicity in older adults with non-Hodgkin lymphoma.
Pallawi Torka, MD, and colleagues investigated whether a geriatric assessment or its component measures can predict toxicity in older adults with non-Hodgkin lymphoma.
Pallawi Torka, MD, and...
02/06/2024
Journal of Clinical Pathways
News
Real-World Clinical Effectiveness of Lisocabtagene Maraleucel in Patients With Relapsed or Refractory Large B-cell Lymphoma
01/30/2024
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and colleagues evaluated the real-world clinical effectiveness and safety of commercial lisocabtagene maraleucel in patients with relapsed or refractory large B-cell lymphoma.
Jennifer L. Crombie, MD, and...
01/30/2024
Journal of Clinical Pathways
News
Efficacy and Safety of Real-World Treatments of Teclistamab for Patients with Pretreated Relapsed/Refractory Multiple Myeloma
01/29/2024
Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed refractory multiple myeloma who have had at least four prior lines of therapy.
Danai Dima, MD, and colleagues examined the real-world safety and efficacy of teclistamab for treating patients with relapsed refractory multiple myeloma who have had at least four prior lines of therapy.
Danai Dima, MD, and colleagues...
01/29/2024
Journal of Clinical Pathways
Video preview thumbnail.
Videos
The Impact of Racial and Socioeconomic Disparities in Patients With Chronic Lymphocytic Leukemia
01/02/2024
Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...
Ira Zackon, MD, New York Oncology Hematology, speaks with the Journal of Clinical Pathways about the abstract he presented at the 2023 ASH Annual Meeting & Exposition titled “Racial and Socioeconomic Disparities Among Patients with Chronic...
Ira Zackon, MD, New York...
01/02/2024
Journal of Clinical Pathways
Conference Coverage
Key Factors Influencing Survival Rates in Patients With Myelofibrosis Undergoing Allogeneic Hematopoietic Stem Cell Transplantation
12/07/2023
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS, and colleagues evaluated the impact of clinical and molecular factors on the outcomes of allogeneic hematopoietic stem cell transplantation in patients with myelofibrosis.
A study by Helen Ajufo, MD, MS,...
12/07/2023
Journal of Clinical Pathways
Conference Coverage
Incidence and Survival Outcomes of Diffuse Large B-Cell Lymphoma in Adolescents and Young Adults
12/07/2023
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted a study to determine the influence of race on the occurrence and survival outcomes of DLBCL among adolescents and young adults.
A team of researchers conducted...
12/07/2023
Journal of Clinical Pathways
News
Disparities in Palliative Care Access Highlighted in Nationwide Study of Deceased Lymphoma Patients
12/04/2023
Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...
Nationwide study reveals that deceased lymphoma patients receiving palliative care experience significantly lower total charges but no significant impact on adjusted length of stay. The research also highlights disparities in access, with...
Nationwide study reveals that...
12/04/2023
Journal of Clinical Pathways
News
Zanubrutinib Shows Superior Long-Term Outcomes vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/04/2023
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and colleagues demonstrated zanubrutinib’s benefits over ibrutinib for patients with chronic lymphocytic leukemia by showing improved progression-free survival and superior cardiac safety over a three-year period.
Jennifer Brown, MD, and...
12/04/2023
Journal of Clinical Pathways
News
Evaluation of First-Line Treatment Outcomes in Elderly Patients with Diffuse Large B-Cell Lymphoma
12/04/2023
Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.
Steven Bair, MD, and colleagues evaluated long-term outcomes across different first-line treatment regimens for elderly patients with DLBCL, including standard dose R-CHOP, reduced dose R-CHOP, and non-anthracycline alternative regimens.
Steven Bair, MD, and colleagues...
12/04/2023
Journal of Clinical Pathways
News
Comparative Study of Nemtabrutinib and Venetoclax for Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
12/04/2023
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will investigate the efficacy and safety of the use of nemtabrutinib and venetoclax in treating relapsed or refractory chronic lymphocytic leukemia.
Dr Lavie and colleagues will...
12/04/2023
Journal of Clinical Pathways
Conference Coverage
Trends in the Use of Bruton Tyrosine Kinase Inhibitors and B-cell 2 Inhibitors for Treating CLL in Community Oncology Settings
11/29/2023
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and colleagues analyzed the implementation and influences of BTKis and BCL2is for treating patients with CLL among community oncologists since 2020.
Jing-Zhou Hou, MD, and...
11/29/2023
Journal of Clinical Pathways
News
Patient-Reported Quality of Life Analyses From the Phase 3 Momentum Study Compares Momelotiniob vs Danazol for the Treatment of Myelofibrosis
03/02/2023
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing danazol vs momelotinib for the treatment of myelofibrosis (MF) found that momelotinib demonstrated greater improvements in disease-related symptoms, physical function, and health-related quality of life among...
A phase 3 study comparing...
03/02/2023
Journal of Clinical Pathways
Conference Coverage
Researchers Present Status of PACIFICA Trial for Treatment of Primary or Secondary Myelofibrosis and Severe Thrombocytopenia
01/31/2023
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting, researchers provided information about the multinational, multicenter, randomized, controlled Phase III PACIFICA trial, which aims to gather data to validate the efficacy and safety of pacritinib vs the...
At the 64th ASH Annual Meeting,...
01/31/2023
Journal of Clinical Pathways
Francesco Maura, MD
Videos
Genomic Mechanism of Resistance Among Patients With Newly Diagnosed Multiple Myeloma Treated With Immunotherapy
01/19/2023
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD, investigated the use of whole genome sequencing to help predict patients with NDMM who may fail to achieve sustained minimal residual disease negativity through unknown resistance mechanisms.
Francesco Maura, MD,...
01/19/2023
Journal of Clinical Pathways
Ira Zackon, MD
Videos
Real-World Treatment Patterns and Overall Survival Among Patients With Higher-Risk Myelodysplastic Syndromes
01/06/2023
Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.
Ira Zackon, MD, discussed his retrospective study which aimed to understand patient characteristics, treatment patterns, and OS of patients with higher-risk MDS treated in the community oncology setting.
Ira Zackon, MD, discussed his...
01/06/2023
Journal of Clinical Pathways
Andrew Hantel, MD
Videos
Defining Disparities Across Catchment Areas for Comprehensive Cancer Centers in Acute Leukemia
01/05/2023
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses race-ethnic disparities in acute leukemia research participation, at the 64th Annual ASH Meeting.
Andrew Hantel, MD, discusses...
01/05/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
The Benefits of Incorporating Radiation Therapy Into the Treatment of Primary CNS Lymphoma
01/05/2023
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting, Kathryn Tringale, MD, MAS, discusses outcomes with reduced-dose whole-brain radiation therapy as a consolidation regimen among patients with primary CNS lymphoma, suggesting the prospect of incorporating...
At the 64th ASH Annual Meeting,...
01/05/2023
Journal of Clinical Pathways
Kathryn Tringale, MD, MAS
Videos
Retrospective Analysis of Survival Outcomes Following Treatment for Primary CNS Lymphoma
01/05/2023
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS, presented her study on patients with primary CNS lymphoma at the 64th Annual ASH Meeting, which analyzed survival outcomes after consolidation regimens and patterns of disease failure among over 500 patients treated...
Kathryn Tringale, MD, MAS,...
01/05/2023
Journal of Clinical Pathways
Robert Rifkin, MD
Videos
Utilizing Real-World Data to Assess the Impact of COVID-19 on Treatment Patterns and Management of Multiple Myeloma
12/21/2022
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his abstract presented at the 64th ASH Annual Meeting on utilizing data from the Connect MM Registry, the oldest and largest myeloma disease-specific registry, to understand changes in the patterns of multiple...
Robert Rifkin, MD, discusses his...
12/21/2022
Journal of Clinical Pathways
Jennifer Brown, MD, PhD
Videos
Efficacy of Zanubrutinib vs Ibrutinib as Treatment for Relapsed/Refractory CLL and SLL
12/21/2022
Jennifer Brown, MD, PhD, found that zanubrutinib may provide further efficacy, safety, and improved progression-free survival compared to ibrutinib among patients with relapsed/refractory CLL and SLL.
Jennifer Brown, MD, PhD, found that zanubrutinib may provide further efficacy, safety, and improved progression-free survival compared to ibrutinib among patients with relapsed/refractory CLL and SLL.
Jennifer Brown, MD, PhD, found...
12/21/2022
Journal of Clinical Pathways
Matthew Maurer, DSc
Videos
Developing a Prognostic Model for Patients With Follicular Lymphoma
12/14/2022
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting, Matthew Maurer, DSc, discussed a prognostic model, the FLIPI24 model, that can identify a high-risk group of patients with FL who are likely to need novel therapies or should be considered for frontline...
At the 64th Annual ASH Meeting,...
12/14/2022
Journal of Clinical Pathways
Mengyang Di, MD, PhD
Videos
Real-World BTK Inhibitor Utilization and Outcomes Following Discontinuation in Older Patients With MCL
12/14/2022
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed a population-based analysis on real-world practice patterns and outcomes following Bruton Tyrosine Kinase Inhibitors in older patients with MCL at the ASH Annual Meeting.
Mengyang Di, MD, PhD, discussed...
12/14/2022
Journal of Clinical Pathways
Conference Coverage
Zanubrutinib vs Ibrutinib in Relapsed/Refractory Chronic Lymphocytic Leukemia and Small Lymphocytic Lymphoma
12/13/2022
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues presented PFS data from the ALPINE study which compared zanubrutinib with ibrutinib as treatment for R/R CLL/SLL at the 64th ASH Annual Meeting and Exposition.
Jennifer R Brown and colleagues...
12/13/2022
Journal of Clinical Pathways
Conference Coverage
Hospital Costs and Health Care Resource Utilization for Chimeric Antigen T-Cell Therapy and Stem Cell Transplant in Patients with Large B-Cell Lymphoma in the United States
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting and Exposition, Gunjan L Shah, MD, described and compared hospital costs and health care resource utilization of chimeric antigen T-cell therapy and stem cell transplant for the procedure, preprocedure, and...
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Analyses of Ibrutinib vs Acalabrutinib vs Zanubrutinib as First-line Treatment in Patients With Chronic Lymphocytic Leukemia
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting and Exposition, Neda Alrawashdh, PharmD, presented a network meta-analysis of three BTKis in terms of progression-free survival in support of cost-effectiveness analyses from the US payer perspective.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
BME Signatures at Baseline and During Treatment Enable Risk Stratifications of Patients With Multiple Myeloma
12/12/2022
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th ASH Annual Meeting and Exposition, Simon Steiger, PhD, and colleagues presented a longitudinal study in which they attempted to associate BME samples with multiple myeloma cytogenic and molecular subgroups.
In a presentation at the 64th...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Isatuximab + Carfilzomib and Dexamethasone in Early vs Late Relapsed Multiple Myeloma
12/12/2022
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at the 64th ASH Annual Meeting and Exposition a subgroup analysis of the phase 3 IKEMA study which examined updated efficacy and safety of isatuximab + carfilzomib (K) and dexamethasone (d) vs Kd in patients with...
Thomas Martin, MD, presented at...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
Comparing BTKis Acalabrutinib and Ibrutinib in Real-World Analysis of Patients With CLL
12/12/2022
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting and Exposition, Lindsey E Roeker, MD, and colleagues present a real-world analysis comparing CV and bleeding AEs as well as PFS in patients with CLL treated with acalabrutinib vs those treated with ibrutinib.
At the 64th ASH Annual Meeting...
12/12/2022
Journal of Clinical Pathways
Conference Coverage
High-Risk Lesions: A Consistent Predictor of Ultra-High Risk Multiple Myeloma
12/11/2022
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP, FRCPath, and colleagues presented at the 2022 ASH Annual Meeting and Exposition to discuss their meta-analysis of randomized clinical trials with extended molecular profiling data for patients with newly diagnosed...
Martin F Kaiser, MD, FRCP,...
12/11/2022
Journal of Clinical Pathways
Conference Coverage
Molecular Variants Associated With Resistance to a Quadruplet Treatment Combination in Newly Diagnosed Multiple Myeloma
12/11/2022
At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.
At the 2022 ASH Annual Meeting, Francesco Maura, MD, and colleagues investigated the molecular variants associated with resistance to a quadruplet treatment combination in patients with newly diagnosed multiple myeloma.
At the 2022 ASH Annual Meeting,...
12/11/2022
Journal of Clinical Pathways
Conference Coverage
Racial and Ethnic Differences in Clinical Outcomes Among Patients With Multiple Myeloma Treated with CAR T Therapy
12/10/2022
At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...
At the 64th ASH Annual Meeting and Exposition, Lauren C Peres, PhD, MPH, and colleagues explore the racial and ethnic differences in safety, efficacy, and outcomes among patients with relapsed/refractory multiple myeloma who were treated with...
At the 64th ASH Annual Meeting...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
No Evidence That BCMA Expression Is Completely Lost Following Belamaf Treatment in Patients With RRMM
12/10/2022
In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...
In a presentation at the 64th Annual ASH Meeting and Exposition, Daniel E Lowther, PhD, and colleagues discuss their study to determine if immune impairment and complete target loss were seen in patients with relapsed/refractory multiple...
In a presentation at the 64th...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
Updated, Longer-term Efficacy Data Following Subsequent Therapy in ICARIA-MM
12/10/2022
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and colleagues presented a study at the 64th ASH Annual Meeting and Exposition and discussed updated and longer-term efficacy data regarding multiple lines of therapy subsequent to ICARIA-MM.
Paul G Richardson, MD, and...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
Bendamustine-Rituximab Followed by Rituximab ± Lenalidomide for Mantle Cell Lymphoma
12/10/2022
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and colleagues presented data at the 64th ASH Annual Meeting and Exposition on whether progression-free survival is prolonged by the addition of bortezomib to bendamustine-rituximab induction and/or by the addition of...
Mitchell R Smith, MD, and...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
A 12-Gene Signature Accurately Predicts Progression From Monoclonal Gammopathy of Undetermined Significance to Multiple Myeloma
12/10/2022
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual Meeting and Exposition, Fumou Sun, PhD, and colleagues discussed a 12-gene score that demonstrated noticeable accuracy in predicting 10-year progression to multiple myeloma in a limited population of patients...
Speaking at the 64th ASH Annual...
12/10/2022
Journal of Clinical Pathways
Conference Coverage
Real-world Outcomes of ASCT in Initial Therapy in Patients With Newly Diagnosed Multiple Myeloma
12/10/2022
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues discuss real-world outcomes of patients treated with autologous stem cell transplant as part of their initial multiple myeloma therapy during their presentation at the 64th ASH Annual Meeting and Exposition.
Julie Cote, MD, and colleagues...
12/10/2022
Journal of Clinical Pathways
Christopher Kim, Amgen
Videos
Real-World Treatments and Outcomes of Triple-Class Relapsed or Refractory MM
01/11/2022
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH, discusses findings from a study which evaluated treatment and outcomes among patients with triple-class relapsed or refractory MM in US community practice.
Christopher Kim, PhD, MPH,...
01/11/2022
Journal of Clinical Pathways
Irena Tan, MD, Stanford Cancer Institute
Videos
Impact of CAR-T Therapy on Quality of Life: Patient-Reported Outcomes vs Performance-Based Metrics
01/11/2022
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study findings comparing the impact of CAR-T therapy on patients’ quality of life, including patient-reported cognitive function and performance-based cognition.
Irena Tan, MD, discusses study...
01/11/2022
Journal of Clinical Pathways
MIchele Muir, PharmD
Videos
Real-World Effectiveness, Safety of Generic vs Branded Imatinib for CML
01/11/2022
Michele Muir, PharmD, discusses results from a study evaluating the effectiveness and safety of generic imatinib compared to branded imatinib for patients with CML in real-world clinical practice.
Michele Muir, PharmD, discusses results from a study evaluating the effectiveness and safety of generic imatinib compared to branded imatinib for patients with CML in real-world clinical practice.
Michele Muir, PharmD, discusses...
01/11/2022
Journal of Clinical Pathways
Kristin Savill, Cardinal Health
Videos
Real-World Treatment With CAR-T Therapies Among Patients With DLBCL
01/11/2022
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses real-world characteristics and treatment outcomes of patients with DLBCL treated with axicabtagene ciloleucel and tisangenlecleucel.
Kristin Savill, PhD, discusses...
01/11/2022
Journal of Clinical Pathways
Muhamad Alhaj Moustafa, MD
Videos
Real-World Utilization and Cost-Effectiveness of Yttrium-90 Ibritumomab Tiuxetan vs Bendamustine Plus Rituximab for FL and MZL
12/16/2021
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD, discusses a real-world study comparing the utilization and cost-effectiveness of yttrium-90 ibritumomab tiuxetan vs bendamustine plus rituximab for the first-line treatment of patients with low grade FL and MZL.
Muhamad Alhaj Moustafa, MD,...
12/16/2021
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness of Lisocabtagene Maraleucel vs Axicabtagene Ciloleucel for Relapsed or Refractory LBCL
12/16/2021
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
Lisocabtagene maraleucel may be cost-effective vs axicabtagene ciloleucel for relapsed or refractory LBCL from a commercial US payer perspective, according to a study presented at 2021 ASH Annual Meeting.
Lisocabtagene maraleucel may be...
12/16/2021
Journal of Clinical Pathways
Matthew Matasar, MD
Videos
Health Care Resource Utilization and Costs Among Patients With FL Receiving Multiple Lines of Therapy
12/15/2021
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses findings from a real-world study examining health care resource utilization and costs among patients with relapsed/refractory FL receiving 3 or more lines of therapy.
Matthew Matasar, MD, discusses...
12/15/2021
Journal of Clinical Pathways
Kerry Rogers, MD
Videos
Real-World Cost and Clinical Burden of Tumor Lysis Syndrome Among Patients With CLL and SLL
12/14/2021
Kerry Rogers, MD, discusses her study on real world-data regarding the cost of treatment for tumor lysis syndrome in patients with CLL and SLL, presented at the 2021 ASH Annual Meeting and Exposition.
Kerry Rogers, MD, discusses her study on real world-data regarding the cost of treatment for tumor lysis syndrome in patients with CLL and SLL, presented at the 2021 ASH Annual Meeting and Exposition.
Kerry Rogers, MD, discusses her...
12/14/2021
Journal of Clinical Pathways
Conference Coverage
First-Line Venetoclax Plus Azacitidine vs Intensive Chemotherapy for Patients With AML in the Real-World Setting
12/11/2021
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
In the real-world setting, use of intensive chemotherapy was more common than venetoclax plus azacitidine for patients aged 60-75 years with AML.
In the real-world setting, use...
12/11/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns and Decision-Making for Patients With MM in the United States
12/08/2021
Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.
Study results presented at the 2021 ASH Annual Meeting provided valuable real-world data on current treatment patterns and decision-making for patients with MM.
Study results presented at the...
12/08/2021
Journal of Clinical Pathways
Conference Coverage
Safety and Cost-Effectiveness of CAR-T Therapy in the Outpatient vs Inpatient Setting
12/08/2021
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the 2021 ASH Annual Meeting demonstrate the feasibility and cost-effectiveness of outpatient administration of CAR-T therapy for patients with hematologic malignancies.
Study findings presented at the...
12/08/2021
Journal of Clinical Pathways
Conference Coverage
Real-World Safety, Efficacy of Belantamab Mafodotin for Relapsed/Refractory MM
12/08/2021
In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.
In the real-world setting, belantamab mafodotin demonstrates comparable responses and toxicities in patients with MM to those seen in clinical trials.
In the real-world setting,...
12/08/2021
Journal of Clinical Pathways
Conference Coverage
Care Team Burden Impact on Treatment Selection for CLL and Lymphoid Malignancies
12/07/2021
Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.
Study findings suggest domain-specific appraisal of electronic communication portals can improve health care delivery and intervention and maximize patient-centered care while decreasing therapy-related health care team burden.
Study findings suggest...
12/07/2021
Journal of Clinical Pathways
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
Videos
Real-World Ibrutinib Dose Reductions, Discontinuations in CLL
03/11/2021
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD, discusses dose reductions and discontinuations between patients with CLL receiving ibrutinib in the community vs academic settings.
Jing-Zhou Hou, MD, PhD,...
03/11/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
Videos
Real-World Treatment Patterns, FLT3 Testing, and Outcomes in AML
01/14/2021
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS, discusses results from a retrospective study examining FLT3 testing trends, treatment patterns, and overall survival in relapsed/refractory AML.
Amer Zeidan, MBBS, MHS,...
01/14/2021
Journal of Clinical Pathways
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
ENGAGING EXPERTS
Real-World Treatment Patterns, HCRU in Patients With CML Achieving Later Lines of Therapy
01/14/2021
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses results from a study evaluating treatment patterns in patients with CML achieving later lines of therapy, and estimating the associated HCRU and costs.
Ehab Atallah, MD, discusses...
01/14/2021
Journal of Clinical Pathways
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
Videos
Real-World Adherence to NCCN Guidelines in Advanced Classical Hodgkin Lymphoma
01/14/2021
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD, discusses real-world adherence to National Comprehensive Cancer Network (NCCN) Guidelines regarding PET/CT usage and reported Deuville scores in advanced stage classical Hodgkin lymphoma.
Christopher Yasenchak, MD,...
01/14/2021
Journal of Clinical Pathways
Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice
Videos
Subcutaneous Rituximab Prefered Over Intravenous Formulation for NHL in Clinical Practice
01/14/2021
01/14/2021
Journal of Clinical Pathways
Conference Coverage
Efficacy, Safety, Cost of Outpatient Transplantation for Patients With MM
12/22/2020
12/22/2020
Journal of Clinical Pathways
Conference Coverage
Comparative- and Cost-Effectiveness of Two Regimens for Relapsed/Refractory MM
12/21/2020
12/21/2020
Journal of Clinical Pathways
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
Videos
Real-World Effectiveness of Enasidenib for Relapsed/Refractory AML
12/21/2020
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH, discusses results from a real-world cohort study confirming the effectiveness of enasidenib for relapsed/refractory AML outside the trial setting.
Andrew Klink, PhD, MPH,...
12/21/2020
Journal of Clinical Pathways
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
Videos
Impact of CAR-T Therapy on HCRU and End-of-Life Outcomes in Hematologic Malignancies
12/20/2020
12/20/2020
Journal of Clinical Pathways
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
Videos
IRd vs Placebo-Rd for Patients With Newly-Diagnosed MM
12/20/2020
12/20/2020
Journal of Clinical Pathways
Conference Coverage
Pre-Transplant MRD Status Predicts PFS, OS in Patients With MCL
12/18/2020
12/18/2020
Journal of Clinical Pathways
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
Videos
HCRU, Costs With CAR-T Therapy Compared to Transplantation for DLBCL
12/17/2020
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses study results that showed greater HCRU and costs with CAR-T therapy than transplantation for patients with relapsed/refractory DLBCL.
Karl Kilgore, PhD, discusses...
12/17/2020
Journal of Clinical Pathways
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
Videos
Real-World Biomarker Testing, Treatment Patterns in CLL/SLL
12/17/2020
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses prognostic biomarker testing, treatment practices, and outcomes among patients with CLL in the clinical practice setting, using the informCLL prospective registry.
Anthony Mato, MD, discusses...
12/17/2020
Journal of Clinical Pathways
First-Line Ibrutinib Demonstrates Long-Term Efficacy in TP53-Mutated CLL
Videos
First-Line Ibrutinib Demonstrates Long-Term Efficacy in TP53-Mutated CLL
12/16/2020
12/16/2020
Journal of Clinical Pathways
Conference Coverage
Rituximab Monotherapy Extends TTNT vs Observation in Advanced FL
12/11/2020
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Rituximab monotherapy improves time-to-next treatment (TTNT) compared with observation in patients with advanced stage follicular lymphoma.
Rituximab monotherapy improves...
12/11/2020
Journal of Clinical Pathways
First-Line Ibrutinib Effective for CLL/SLL Irrespective of Cytogenetic or Mutational Risk Features
ENGAGING EXPERTS
First-Line Ibrutinib Effective for CLL/SLL Irrespective of Cytogenetic or Mutational Risk Features
12/10/2020
12/10/2020
Journal of Clinical Pathways
Conference Coverage
Cost-Effectiveness Comparison of BTK Inhibitors for MCL
12/09/2020
12/09/2020
Journal of Clinical Pathways
Conference Coverage
Real-World Toxicity and Tolerability of Ibrutinib for CLL or SLL
12/09/2020
12/09/2020
Journal of Clinical Pathways
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
Videos
Real-World Comparison of DRd and DPd for Relapsed/Refractory MM
12/09/2020
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD, presents findings from a study comparing daratumumab plus lenalidomide and dexamethasone (DRd) vs daratumumab plus pomalidomide and dexamethasone (DPd) for lenalidomide-exposed patients with relapsed or refractory...
Muhamad Alhaj Moustafa, MD,...
12/09/2020
Journal of Clinical Pathways
Conference Coverage
Adding Rituximab to Anthracycline-Based Chemotherapy Increases PFS, OS in FL
12/09/2020
12/09/2020
Journal of Clinical Pathways
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
Videos
Real-World Comparison of Costs, Outcomes of LBCL With or Without Transplantation
12/09/2020
12/09/2020
Journal of Clinical Pathways
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
Videos
HCRU and Costs Associated With CAR-T Therapy Toxicity Management in MM
12/08/2020
12/08/2020
Journal of Clinical Pathways
Conference Coverage
Emory MRD Decision Framework Saves Costs, Improves Health Outcomes in MM
12/08/2020
12/08/2020
Journal of Clinical Pathways
Conference Coverage
Increased Use of Maintenance Therapy Following Transplantation for MM in US Clinical Practice
12/08/2020
12/08/2020
Journal of Clinical Pathways
Daratumumab Plus RVd Continues to Demonstrate Improved Responses in MM
Videos
Daratumumab Plus RVd Continues to Demonstrate Improved Responses in MM
12/07/2020
12/07/2020
Journal of Clinical Pathways
Daratumumab Plus VCd Improves Responses in Newly Diagnosed AL Amyloidosis
Videos
Daratumumab Plus VCd Improves Responses in Newly Diagnosed AL Amyloidosis
12/07/2020
12/07/2020
Journal of Clinical Pathways
Conference Coverage
Comparison of HCRU and Costs Associated With Treatments for Relapsed/Refractory DLBCL
12/06/2020
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with CAR-T therapy were greater than transplantation for DLBCL and cost offsets before and after the procedures provide useful insight for treatment planning.
HCRU and costs associated with...
12/06/2020
Journal of Clinical Pathways
Conference Coverage
Enasidenib Effective for Relapsed/Refractory IDH2-Mutated AML in Real-World Setting
12/06/2020
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study confirm the effectiveness of first-line enasidenib therapy for patients with relapsed/refractory IDH2-mutated AML outside of the trial setting.
Results from a real-world study...
12/06/2020
Journal of Clinical Pathways
Real-World Outcomes of First-Line Ibrutinib vs Chemoimmunotherapy for CLL
ENGAGING EXPERTS
Real-World Outcomes of First-Line Ibrutinib vs Chemoimmunotherapy for CLL
12/06/2020
12/06/2020
Journal of Clinical Pathways
Conference Coverage
Polatuzumab Vedotin Plus Bendamustine-Rituximab Cost-Effective for DLBCL
12/05/2020
12/05/2020
Journal of Clinical Pathways
Conference Coverage
Real-World Treatment Patterns, Health Care Resource Utilization, and Costs in CML
12/05/2020
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching to the subsequent lines of therapy is frequent due to previous TKI intolerance and results in high medical costs.
For patients with CML, switching...
12/05/2020
Journal of Clinical Pathways
Belantamab Mafodotin Plus Bortezomib and Dexamethasone for Relapsed/Refractory MM
Videos
Belantamab Mafodotin Plus Bortezomib and Dexamethasone for Relapsed/Refractory MM
12/04/2020
12/04/2020
Journal of Clinical Pathways
Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM
Videos
Adding Daratumumab to Pomalidomide and Dexamethasone Improves PFS in Relapsed/Refractory MM
12/04/2020
12/04/2020
Journal of Clinical Pathways
Conference Coverage
Ibrutinib Dose Reductions and Discontinuations for CLL in Routine Practice vs Clinical Trials
12/04/2020
12/04/2020
Journal of Clinical Pathways
Conference Coverage
Watch and Wait vs Initial Treatment for Advanced FL
12/03/2020
12/03/2020
Journal of Clinical Pathways
Conference Coverage
Treatment Sequencing Impact on Outcomes and Costs in Relapsed/Refractory FL
11/30/2020
11/30/2020
Journal of Clinical Pathways
JCP September/October 2024 Issue

Current Issue

October 2024
Volume 10
Issue 5
Current Issue
Issue Archive

Special Reports

Subscribe

Journal of Clinical Pathways Newsletter

Specialties

Events

Year Round Education

HMP Global Products

HMP Education Logo
HMP Omnimedia Logo
HMP Europe Logo
© 2024 HMP Global. All Rights Reserved.
Cookie Policy Privacy Policy Term of Use